Antiganglioside antibody frequency in routine clinical care settings.
Guillain–Barré syndrome
ganglioside
nervous system
neurology
polyneuropathy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
31 Mar 2024
31 Mar 2024
Historique:
revised:
23
02
2024
received:
19
12
2023
accepted:
14
03
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Antiganglioside antibodies (AGAs) might be involved in the etiopathogenesis of many neurological diseases, such as Miller-Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS). Available comprehensive reference data regarding AGA positivity rates and cross-responsiveness among AGAs (where one line immunoblot is positive for ≥1 AGA) during routine clinical care are scant. In this 10-year monocentric retrospective study, 3560 immunoglobulin (Ig) G and IgM line blots (GA Generic Assays' Anti-Ganglioside Dot kit) obtained using cerebrospinal fluid (CSF) and serum samples from 1342 patients were analyzed for AGA positivity in terms of 14 diagnosis categories and AGA cross-responsiveness. Of all 3560 line blots 158 (4.4%) and of all CSF samples 0.4% (4/924) CSF line blots were AGA positive. For serum IgG, blots with positivity rates higher than the standard deviation of 15.6% were associated with MFS (GD3, GD1a, GT1a and GQ1b) and acute motor axonal neuropathy (AMAN) (GM1, GD1a and GT1a). For serum IgM, blots with positivity rates higher than the standard deviation of 8.1% were associated with AMAN (GM2, GT1a and GQ1b), MFS (GM1, GT1a and GQ1b), multifocal motor neuropathy (MMN) (GM1, GM2 and GQ1b) and chronic inflammatory demyelinating polyneuropathy (CIDP) (GM1). Cross-responsiveness was observed in 39.6% of all positive serum AGA. Testing for AGAs during routine clinical care rarely led to positive findings, both in serum and even less in CSF, except for the diagnoses AMAN, MFS, MMN and CIDP. Nonspecific findings found as cross-responsiveness between different AGA samples occur frequently, impacting the positivity of most AGA subtypes.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Antiganglioside antibodies (AGAs) might be involved in the etiopathogenesis of many neurological diseases, such as Miller-Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS). Available comprehensive reference data regarding AGA positivity rates and cross-responsiveness among AGAs (where one line immunoblot is positive for ≥1 AGA) during routine clinical care are scant.
METHODS
METHODS
In this 10-year monocentric retrospective study, 3560 immunoglobulin (Ig) G and IgM line blots (GA Generic Assays' Anti-Ganglioside Dot kit) obtained using cerebrospinal fluid (CSF) and serum samples from 1342 patients were analyzed for AGA positivity in terms of 14 diagnosis categories and AGA cross-responsiveness.
RESULTS
RESULTS
Of all 3560 line blots 158 (4.4%) and of all CSF samples 0.4% (4/924) CSF line blots were AGA positive. For serum IgG, blots with positivity rates higher than the standard deviation of 15.6% were associated with MFS (GD3, GD1a, GT1a and GQ1b) and acute motor axonal neuropathy (AMAN) (GM1, GD1a and GT1a). For serum IgM, blots with positivity rates higher than the standard deviation of 8.1% were associated with AMAN (GM2, GT1a and GQ1b), MFS (GM1, GT1a and GQ1b), multifocal motor neuropathy (MMN) (GM1, GM2 and GQ1b) and chronic inflammatory demyelinating polyneuropathy (CIDP) (GM1). Cross-responsiveness was observed in 39.6% of all positive serum AGA.
CONCLUSIONS
CONCLUSIONS
Testing for AGAs during routine clinical care rarely led to positive findings, both in serum and even less in CSF, except for the diagnoses AMAN, MFS, MMN and CIDP. Nonspecific findings found as cross-responsiveness between different AGA samples occur frequently, impacting the positivity of most AGA subtypes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16290Subventions
Organisme : University of Tuebingen
ID : 45800
Informations de copyright
© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Klenk E. Über die Natur der Phosphatide und anderer Lipoide des Gehirns und der Leber bei der Niemann–Pickschen Krankheit. [12. Mitteilung über Phosphatide.]. Hoppe‐Seyler's Zeitschrift für Physiologische Chem. 1935;235(1–2):24‐36. doi:10.1515/bchm2.1935.235.1-2.24
Sonnino S, Mauri L, Chigorno V, Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology. 2007;17(1):1R‐13R. doi:10.1093/glycob/cwl052
Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965. doi:10.3389/fnins.2020.572965
Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides—an overview. J Oleo Sci. 2011;60(10):537‐544. doi:10.5650/jos.60.537
Ho TW, Willison HJ, Nachamkin I, et al. Anti‐GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barré syndrome. Ann Neurol. 1999;45(2):168‐173.
Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31(6):677‐679. doi:10.1002/ana.410310619
Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol. 1998;44(6):980‐983. doi:10.1002/ana.410440621
Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24(1):73‐78. doi:10.1002/ana.410240113
Kimura F, Ito T, Yuki N, et al. Longitudinal study of serum and cerebrospinal fluid (CSF) class‐specific antibodies against Campylobacter jejuni and GM1 ganglioside in Guillain–Barré syndrome. Intern Med. 1995;34(10):1009‐1014. doi:10.2169/internalmedicine.34.1009
Finsterer J. Triggers of Guillain–Barré syndrome: Campylobacter jejuni predominates. IJMS. 2022;23(22):14222. doi:10.3390/ijms232214222
Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA. 2004;101(31):11404‐11409. doi:10.1073/pnas.0402391101
Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain–Barré syndrome and Miller Fisher syndrome. J Infect Dis. 1997;176(s2):S150‐S153. doi:10.1086/513800
Zhu W, Li K, Cui T, Yan Y. Detection of anti‐ganglioside antibodies in Guillain–Barré syndrome. Ann Transl Med. 2023;11(7):289. doi:10.21037/atm-20-2285
Bonyadi MR, Barzegar M, Badalzadeh R, Hashemilar M. Comparison of immunoblotting and ELISA for detection of anti‐ganglioside antibodies in children with Guillain–Barré syndrome. Iran J Immunol. 2010;7(2):117‐123.
Lleixà C, Martín‐Aguilar L, Pascual‐Goñi E, et al. Autoantibody screening in Guillain–Barré syndrome. J Neuroinflammation. 2021;18(1):251. doi:10.1186/s12974-021-02301-0
Van Doorn PA, Van Den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome. J Peripheral Nervous Sys. 2023;28(4):535‐563. doi:10.1111/jns.12594
Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti‐GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993;43(10):1911. doi:10.1212/WNL.43.10.1911
Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti‐GQ1b antibody in Fisher's syndrome. Neurology. 1993;43(2):414. doi:10.1212/WNL.43.2.414
Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol. 2008;255(5):674‐682. doi:10.1007/s00415-008-0775-0
Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti‐GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. 2013;84(5):576‐583. doi:10.1136/jnnp-2012-302824
Bourque PR, Chardon JW, Massie R. Autoimmune peripheral neuropathies. Clin Chim Acta. 2015;449:37‐42. doi:10.1016/j.cca.2015.02.039
Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti‐GT1a IgG antibodies. J Neurol Sci. 2004;219(1–2):139‐145. doi:10.1016/j.jns.2004.01.005
Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol. 1999;100(1–2):3‐12. doi:10.1016/S0165-5728(99)00213-1
Willison HJ. Fine specificity of anti‐GQ1b antibodies and clinical features. J Neurol Sci. 2001;185(1):1‐2. doi:10.1016/S0022-510X(01)00465-8
Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: association of anti‐GM1 IgM antibodies with clinical features. Neurology. 2010;75(22):1961‐1967. doi:10.1212/WNL.0b013e3181ff94c2
Nobile‐Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 2001;115(1–2):4‐18. doi:10.1016/S0165-5728(01)00266-1
Léger JM, Guimarães‐Costa R, Iancu Ferfoglia R. The pathogenesis of multifocal motor neuropathy and an update on current management options. Ther Adv Neurol Disord. 2015;8(3):109‐122. doi:10.1177/1756285615575269
Uncini A, Notturno F, Capasso M. Natura non Facit Saltus in anti‐ganglioside antibody‐mediated neuropathies. Muscle Nerve. 2013;48(4):484‐487. doi:10.1002/mus.23881
Nobile‐Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta C, Carpo M. How useful are anti‐neural IgM antibodies in the diagnosis of chronic immune‐mediated neuropathies? J Neurol Sci. 2008;266(1–2):156‐163. doi:10.1016/j.jns.2007.09.020
Van Den Bergh PYK, Van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force—second revision. J Peripheral Nervous Sys. 2021;26(3):242‐268. doi:10.1111/jns.12455
Mata S, Galli E, Amantini A, Pinto F, Sorbi S, Lolli F. Anti‐ganglioside antibodies and elevated CSF IgG levels in Guillain–Barré syndrome. Eur J Neurol. 2006;13(2):153‐160. doi:10.1111/j.1468-1331.2006.01161.x
Simone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P. Serum and CSF anti‐GM1 antibodies in patients with Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 1993;114(1):49‐55. doi:10.1016/0022-510X(93)90048-4
Spatola M, Du Pasquier R, Schluep M, Regeniter A. Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes. Neurology. 2016;86(19):1780‐1784. doi:10.1212/WNL.0000000000002558